Drug profile · INN
ganaxolone
ZTALMY
ganaxolone (ZTALMY) is a gaba-a receptor; anion channel positive allosteric modulator. Route of administration: oral. Current US regulatory status: approved.
Drug details — ganaxolone
- US status
- approved
- Class
- Nervous system (N03)
- Route
- ORAL
- Patents
- 2
- Programs
- 0
- Data quality
- 0.84
Quick answer
ganaxolone (ZTALMY) is a gaba-a receptor; anion channel positive allosteric modulator. Route of administration: oral. Current US regulatory status: approved.
Key facts
Mechanism of action
GABA-A receptor; anion channel positive allosteric modulator
Primary target: GABA-A receptor; anion channel
Approval history
| Authority | Status | Date |
|---|---|---|
| FDA | approved | — |
| EMA | approved | — |
Recent coverage
Related & competitor drugs
Related patents
Frequently asked questions
What is ganaxolone?
ganaxolone (ZTALMY) is a gaba-a receptor; anion channel positive allosteric modulator. Route of administration: oral. Current US regulatory status: approved.
What is the brand name for ganaxolone?
ZTALMY is a marketed brand name for ganaxolone. Check FDA Drugs@FDA for the current US label holder and prescribing information.
What is the US approval status of ganaxolone?
ganaxolone has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.